<DOC>
	<DOCNO>NCT00094523</DOCNO>
	<brief_summary>This study design evaluate compare safety , tolerability subject successfully suppress HIV-1 first PI regimen switch fosamprenavir . This 48-week study , subject assign original PI-group option switch fosamprenavir week 24 . Prior assign treatment group , subject suppress least three month . All subject also take background regimen two nucleoside/nucleotide reverse transcriptase inhibitor .</brief_summary>
	<brief_title>Fosamprenavir Versus Other Protease Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Be first protease inhibitor ( PI ) contain regimen , regimen must consist PI +/ ritonavir 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors ( N [ ] RTIs ) . Have plasma HIV1 RNA level ( viral load ) screen less 400 copies/mL , least 3 month prior Screening Screening current regimen PI +/ ritonavir + 2 N ( ) RTIs . Females must pregnant breastfeeding plan become pregnant study . Females childbearing potential must agree use one approve method birth control . Not able follow medication schedule attend study visit entire length study . Have illness , laboratory test result , medication use , allergy , medical condition would make unsafe subject participate study . Currently enrol research study could affect subject '' ''s HIV1 RNA level .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>fosamprenavir LEXIVA non-inferiority safety tolerability</keyword>
</DOC>